E
Eva Herrmann
Researcher at Goethe University Frankfurt
Publications - 459
Citations - 18901
Eva Herrmann is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Medicine & Hepatitis C virus. The author has an hindex of 66, co-authored 406 publications receiving 16438 citations. Previous affiliations of Eva Herrmann include Saarland University & Technische Universität Darmstadt.
Papers
More filters
Journal ArticleDOI
Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis
Mireen Friedrich-Rust,Mei-Fang Ong,Swantje Martens,Christoph Sarrazin,Joerg Bojunga,Stefan Zeuzem,Eva Herrmann +6 more
TL;DR: Transient elastography can be performed with excellent diagnostic accuracy and independent of the underlying liver disease for the diagnosis of cirrhosis, however, for the diagnoses of significant fibrosis, a high variation of the AUROC was found that is dependent on the underlying Liver disease.
Journal ArticleDOI
Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography
Mireen Friedrich-Rust,Katrin Wunder,Susanne Kriener,Fariba Sotoudeh,Swantje Richter,Joerg Bojunga,Eva Herrmann,Thierry Poynard,Christoph F. Dietrich,Johannes Vermehren,Stefan Zeuzem,Christoph Sarrazin +11 more
TL;DR: ARFI imaging is a promising US-based method for assessing liver fibrosis in chronic viral hepatitis, with diagnostic accuracy comparable to that of TE in this preliminary study.
Journal ArticleDOI
Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.
Christian F Weber,Klaus Görlinger,Dirk Meininger,Eva Herrmann,Tobias M. Bingold,Anton Moritz,Lawrence H. Cohn,Kai Zacharowski +7 more
TL;DR: Hemostatic therapy based on POC testing reduced patient exposure to allogenic blood products and provided significant benefits with respect to clinical outcomes.
Journal ArticleDOI
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
Michael von Wagner,Miriam Huber,Thomas Berg,Holger Hinrichsen,Jens Rasenack,Tobias Heintges,A. Bergk,Christine Bernsmeier,Dieter Häussinger,Eva Herrmann,Stefan Zeuzem +10 more
TL;DR: In HCV-2 and -3 (low viral load)-infected patients who have a rapid virologic response, treatment for 16 weeks with peginterferon-α-2a and ribavirin is sufficient, and in patients infected by HCv-3 (high viral load), longer treatment may be necessary.
Journal ArticleDOI
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis.
Mireen Friedrich-Rust,J. Nierhoff,Monica Lupsor,Ioan Sporea,Carmen Fierbinteanu-Braticevici,Deike Strobel,Hirokazu Takahashi,Masato Yoneda,Takeshi Suda,Stefan Zeuzem,Eva Herrmann +10 more
TL;DR: A systematic review and meta‐analysis of pooled patient data were performed to evaluate the overall performance of ARFI for the staging of liver fibrosis and found it can be performed with good diagnostic accuracy for the noninvasive staging of Liver fibrosis.